Skip to main content

NCBiotech Goes to BIO 2017

This post will be updated with news, stories and observations from the Biotechnology Innovation Organization's 2017 conference in San Diego, June 19-22.


Humacyte Tabbed as ‘Technology Pioneer’ by World Economic Forum

Humacyte, a Morrisville-based regenerative medicine company, has been selected as one of the World Economic Forum’s 30 “Technology Pioneers” for 2017.

US Military Special Operations Forces Have Special Needs

The U.S. Special Operations Forces, which include Navy Seals, Army Rangers, and Air Force Special Tactics, have 9,500 people deployed in 90 countries. So they have special needs when it comes to acquisitions from private-sector partners.

Achelios Gets FDA Guidance on Approval Path for Migraine Drug

Achelios Therapeutics of Chapel Hill has completed a meeting with the U.S. Food and Drug Administration about a path to approval for its leading drug candidate, TOPOFEN, to treat acute and chronic migraine, a condition known for its debilitating pain.

Event Promotes NC Business, US Military Partnerships

One thing was clear, from the opening keynote to the final session, after a unique gathering of North Carolina business and Pentagon procurement leaders: the military is actively seeking private-sector partners to support the health and healing of U.S. warfighters and their families.

CivaTech’s Radiation Device Tested in First Pancreatic Cancer Patient

A Virginia man has become the first person in the world to be treated for pancreatic cancer with a bio-absorbable, implantable radiation device called CivaSheet, developed by Durham-based CivaTech Oncology.


Liquidia’s Opioid Alternative Fares Well in Phase 1 Trial

Morrisville-based Liquidia Technologies has reported positive initial results from a phase 1 clinical trial of a drug candidate for relieving post-surgery pain as an alternative to addictive opioids.

Welcome to the Landing Pad, Fluidigm!

The North Carolina Biotechnology Center is pleased to welcome our newest Landing Pad tenant, Fluidigm.

NCBiotech Portfolio Company G1 Therapeutics Raises $105M in IPO

G1 Therapeutics, a clinical-stage oncology company based in Research Triangle Park, became a publicly traded entity today with a $105 million initial public offering of seven million shares of stock priced at $15 a share.

Kansas Startups Take Awards at NCBiotech Ag Biotech Showcase

Two Kansas startup companies won the top prizes at NCBiotech's two-day 2017 Ag Biotech Entrepreneurial Showcase in Durham.


Subscribe to RSS - NCBiotech